DING-CHENG CHANLin, Yuan-ChengYuan-ChengLinTzeng, Huei-PingHuei-PingTzengRONG-SEN YANGChiang, Meng-TsanMeng-TsanChiangSHING-HWA LIU2024-11-112024-11-112024-08https://scholars.lib.ntu.edu.tw/handle/123456789/722937Diabetic muscular atrophy is becoming a fast-growing problem worldwide, including sarcopenia, which is associated with substantial mortality and morbidity risk. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been marketed and suggested to exert protective effects on not only glycemic control but also diabetic complications in diabetic patients. In this study, we investigated the therapeutic use of GLP-1RAs exendin-4, compared to antidiabetic drug metformin, for the intervention of muscular dysfunction during diabetic conditions using a streptozotocin (STZ)-induced diabetic mouse model. The results showed that both exendin-4 and metformin could effectively alleviate hyperglycemia in diabetic mice, and also counteract diabetes-induced muscle weight loss, weaker grip, and changes in muscle fiber cross-sectional area distribution. Unexpectedly, exendin-4, but not metformin, enhanced the increased kidney weight and histological change in diabetic mice. Taken together, these findings suggest that both exendin-4 and metformin could effectively improve the diabetic hyperglycemia and muscular dysfunction; but exendin-4 may aggravate the nephropathy in STZ-induced diabetic mice.enDiabetic muscular atrophyDiabetic nephropathyExentin-4Glucagon-like peptide-1 receptor agonistMetformin[SDGs]SDG3journal article10.1016/j.tice.2024.10247939018713